Evaluation of the effects of human leukocyte IFN-α on the immune response to the HBV vaccine in healthy unvaccinated individuals

Paola Rizza; Imerio Capone; Francesca Urbani; Enrica Montefiore; Maria Rapicetta; Paola Chionne; Angela Candido; Maria Elena Tosti; Maria Grimaldi; Ernesto Palazzini; Giuseppe Viscomi; Carmela Cursaro; Marzia Margotti; Alessandra Scuteri; Pietro Andreone; Elisabeth Taylor; Elisabeth A. Haygreen; David F. Tough; Persephone Borrow; Marina Selleri; Concetta Castilletti; Maria Capobianchi; Filippo Belardelli

doi:10.1016/j.vaccine.2007.12.044

Evaluation of the effects of human leukocyte IFN-α on the immune response to the HBV vaccine in healthy unvaccinated individuals

Paola Rizza, Imerio Capone, Francesca Urbani, Enrica Montefiore, Maria Rapicetta, Paola Chionne, Angela Candido, Maria Elena Tosti, Maria Grimaldi, Ernesto Palazzini, Giuseppe Viscomi, Carmela Cursaro, Marzia Margotti, Alessandra Scuteri, Pietro Andreone, Elisabeth Taylor, Elisabeth A. Haygreen, David F. Tough, Persephone Borrow, Marina SelleriConcetta Castilletti, Maria Capobianchi, Filippo Belardelli

Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani

Research output: Contribution to journal › Article › peer-review

Abstract

HBV vaccine needs 3 injections over 6 months to induce immunity. Thus, the use of adjuvants capable of inducing earlier immune protection would be highly desirable. Most adjuvants may act by inducing cytokines, and among them, type I interferons (IFNs), deserve a special attention in view of the potent immunomostimulatory activity observed in mouse models and on dendritic cell functions. The aim of the present trial was to evaluate the effects of IFN-α administered as an adjuvant of HBV vaccine in healthy unvaccinated individuals. No significant enhancing effect on the antibody response was observed, in spite of an early and transient upregulation of costimulatory molecule expression on peripheral blood mononuclear cells, which may be suggestive of an IFN-mediated activation of antigen presenting cells. We conclude that, under the conditions used in this trial, natural IFN-α does not act as an adjuvant of the HBV vaccine in healthy unvaccinated individuals.

Original language	English
Pages (from-to)	1038-1049
Number of pages	12
Journal	Vaccine
Volume	26
Issue number	8
DOIs	https://doi.org/10.1016/j.vaccine.2007.12.044
Publication status	Published - Feb 20 2008

Keywords

Adjuvant
Interferon
Vaccine

ASJC Scopus subject areas

Immunology
Microbiology
Virology
Infectious Diseases
Public Health, Environmental and Occupational Health
veterinary(all)

Access to Document

10.1016/j.vaccine.2007.12.044

Fingerprint Dive into the research topics of 'Evaluation of the effects of human leukocyte IFN-α on the immune response to the HBV vaccine in healthy unvaccinated individuals'. Together they form a unique fingerprint.

Cite this

Rizza, P., Capone, I., Urbani, F., Montefiore, E., Rapicetta, M., Chionne, P., Candido, A., Tosti, M. E., Grimaldi, M., Palazzini, E., Viscomi, G., Cursaro, C., Margotti, M., Scuteri, A., Andreone, P., Taylor, E., Haygreen, E. A., Tough, D. F., Borrow, P., ... Belardelli, F. (2008). Evaluation of the effects of human leukocyte IFN-α on the immune response to the HBV vaccine in healthy unvaccinated individuals. Vaccine, 26(8), 1038-1049. https://doi.org/10.1016/j.vaccine.2007.12.044

Evaluation of the effects of human leukocyte IFN-α on the immune response to the HBV vaccine in healthy unvaccinated individuals. / Rizza, Paola; Capone, Imerio; Urbani, Francesca; Montefiore, Enrica; Rapicetta, Maria; Chionne, Paola; Candido, Angela; Tosti, Maria Elena; Grimaldi, Maria; Palazzini, Ernesto; Viscomi, Giuseppe; Cursaro, Carmela; Margotti, Marzia; Scuteri, Alessandra; Andreone, Pietro; Taylor, Elisabeth; Haygreen, Elisabeth A.; Tough, David F.; Borrow, Persephone; Selleri, Marina ; Castilletti, Concetta ; Capobianchi, Maria; Belardelli, Filippo.

In: Vaccine, Vol. 26, No. 8, 20.02.2008, p. 1038-1049.

Research output: Contribution to journal › Article › peer-review

Rizza, P, Capone, I, Urbani, F, Montefiore, E, Rapicetta, M, Chionne, P, Candido, A, Tosti, ME, Grimaldi, M, Palazzini, E, Viscomi, G, Cursaro, C, Margotti, M, Scuteri, A, Andreone, P, Taylor, E, Haygreen, EA, Tough, DF, Borrow, P, Selleri, M , Castilletti, C , Capobianchi, M & Belardelli, F 2008, 'Evaluation of the effects of human leukocyte IFN-α on the immune response to the HBV vaccine in healthy unvaccinated individuals', Vaccine, vol. 26, no. 8, pp. 1038-1049. https://doi.org/10.1016/j.vaccine.2007.12.044

Rizza, Paola ; Capone, Imerio ; Urbani, Francesca ; Montefiore, Enrica ; Rapicetta, Maria ; Chionne, Paola ; Candido, Angela ; Tosti, Maria Elena ; Grimaldi, Maria ; Palazzini, Ernesto ; Viscomi, Giuseppe ; Cursaro, Carmela ; Margotti, Marzia ; Scuteri, Alessandra ; Andreone, Pietro ; Taylor, Elisabeth ; Haygreen, Elisabeth A. ; Tough, David F. ; Borrow, Persephone ; Selleri, Marina ; Castilletti, Concetta ; Capobianchi, Maria ; Belardelli, Filippo. / Evaluation of the effects of human leukocyte IFN-α on the immune response to the HBV vaccine in healthy unvaccinated individuals. In: Vaccine. 2008 ; Vol. 26, No. 8. pp. 1038-1049.

@article{217084bbfc864616a2457b517e28904e,

title = "Evaluation of the effects of human leukocyte IFN-α on the immune response to the HBV vaccine in healthy unvaccinated individuals",

abstract = "HBV vaccine needs 3 injections over 6 months to induce immunity. Thus, the use of adjuvants capable of inducing earlier immune protection would be highly desirable. Most adjuvants may act by inducing cytokines, and among them, type I interferons (IFNs), deserve a special attention in view of the potent immunomostimulatory activity observed in mouse models and on dendritic cell functions. The aim of the present trial was to evaluate the effects of IFN-α administered as an adjuvant of HBV vaccine in healthy unvaccinated individuals. No significant enhancing effect on the antibody response was observed, in spite of an early and transient upregulation of costimulatory molecule expression on peripheral blood mononuclear cells, which may be suggestive of an IFN-mediated activation of antigen presenting cells. We conclude that, under the conditions used in this trial, natural IFN-α does not act as an adjuvant of the HBV vaccine in healthy unvaccinated individuals.",

keywords = "Adjuvant, Interferon, Vaccine",

author = "Paola Rizza and Imerio Capone and Francesca Urbani and Enrica Montefiore and Maria Rapicetta and Paola Chionne and Angela Candido and Tosti, {Maria Elena} and Maria Grimaldi and Ernesto Palazzini and Giuseppe Viscomi and Carmela Cursaro and Marzia Margotti and Alessandra Scuteri and Pietro Andreone and Elisabeth Taylor and Haygreen, {Elisabeth A.} and Tough, {David F.} and Persephone Borrow and Marina Selleri and Concetta Castilletti and Maria Capobianchi and Filippo Belardelli",

year = "2008",

month = feb,

day = "20",

doi = "10.1016/j.vaccine.2007.12.044",

language = "English",

volume = "26",

pages = "1038--1049",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "8",

}

TY - JOUR

T1 - Evaluation of the effects of human leukocyte IFN-α on the immune response to the HBV vaccine in healthy unvaccinated individuals

AU - Rizza, Paola

AU - Capone, Imerio

AU - Urbani, Francesca

AU - Montefiore, Enrica

AU - Rapicetta, Maria

AU - Chionne, Paola

AU - Candido, Angela

AU - Tosti, Maria Elena

AU - Grimaldi, Maria

AU - Palazzini, Ernesto

AU - Viscomi, Giuseppe

AU - Cursaro, Carmela

AU - Margotti, Marzia

AU - Scuteri, Alessandra

AU - Andreone, Pietro

AU - Taylor, Elisabeth

AU - Haygreen, Elisabeth A.

AU - Tough, David F.

AU - Borrow, Persephone

AU - Selleri, Marina

AU - Castilletti, Concetta

AU - Capobianchi, Maria

AU - Belardelli, Filippo

PY - 2008/2/20

Y1 - 2008/2/20

N2 - HBV vaccine needs 3 injections over 6 months to induce immunity. Thus, the use of adjuvants capable of inducing earlier immune protection would be highly desirable. Most adjuvants may act by inducing cytokines, and among them, type I interferons (IFNs), deserve a special attention in view of the potent immunomostimulatory activity observed in mouse models and on dendritic cell functions. The aim of the present trial was to evaluate the effects of IFN-α administered as an adjuvant of HBV vaccine in healthy unvaccinated individuals. No significant enhancing effect on the antibody response was observed, in spite of an early and transient upregulation of costimulatory molecule expression on peripheral blood mononuclear cells, which may be suggestive of an IFN-mediated activation of antigen presenting cells. We conclude that, under the conditions used in this trial, natural IFN-α does not act as an adjuvant of the HBV vaccine in healthy unvaccinated individuals.

AB - HBV vaccine needs 3 injections over 6 months to induce immunity. Thus, the use of adjuvants capable of inducing earlier immune protection would be highly desirable. Most adjuvants may act by inducing cytokines, and among them, type I interferons (IFNs), deserve a special attention in view of the potent immunomostimulatory activity observed in mouse models and on dendritic cell functions. The aim of the present trial was to evaluate the effects of IFN-α administered as an adjuvant of HBV vaccine in healthy unvaccinated individuals. No significant enhancing effect on the antibody response was observed, in spite of an early and transient upregulation of costimulatory molecule expression on peripheral blood mononuclear cells, which may be suggestive of an IFN-mediated activation of antigen presenting cells. We conclude that, under the conditions used in this trial, natural IFN-α does not act as an adjuvant of the HBV vaccine in healthy unvaccinated individuals.

KW - Adjuvant

KW - Interferon

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=39149107091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39149107091&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2007.12.044

DO - 10.1016/j.vaccine.2007.12.044

M3 - Article

C2 - 18249478

AN - SCOPUS:39149107091

VL - 26

SP - 1038

EP - 1049

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 8

ER -